Waters (WAT) Expected to Announce Quarterly Earnings on Thursday

Waters (NYSE:WAT) is expected to issue its Q4 2025 results before the market opens on Thursday, February 12th. Analysts expect the company to announce earnings of $4.50 per share and revenue of $928.1690 million for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Monday, February 9, 2026 at 8:30 AM ET.

Waters (NYSE:WAT) last released its quarterly earnings results on Tuesday, November 4th. The medical instruments supplier reported $3.40 EPS for the quarter, beating analysts’ consensus estimates of $3.21 by $0.19. Waters had a return on equity of 36.59% and a net margin of 20.89%.The company had revenue of $799.89 million during the quarter, compared to analysts’ expectations of $780.05 million. During the same period last year, the business posted $2.93 earnings per share. The firm’s revenue was up 8.1% compared to the same quarter last year. On average, analysts expect Waters to post $13 EPS for the current fiscal year and $14 EPS for the next fiscal year.

Waters Price Performance

Shares of WAT stock opened at $384.62 on Thursday. Waters has a fifty-two week low of $275.05 and a fifty-two week high of $417.10. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.08 and a current ratio of 1.53. The firm has a market capitalization of $22.90 billion, a price-to-earnings ratio of 35.35, a PEG ratio of 3.17 and a beta of 1.18. The stock’s 50-day simple moving average is $388.89 and its 200-day simple moving average is $345.63.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on WAT shares. Wolfe Research upgraded shares of Waters from a “peer perform” rating to an “outperform” rating and set a $480.00 price target on the stock in a research note on Wednesday, December 10th. JPMorgan Chase & Co. boosted their price objective on shares of Waters from $300.00 to $325.00 and gave the company a “neutral” rating in a report on Thursday, October 9th. Wells Fargo & Company upped their target price on Waters from $385.00 to $415.00 and gave the company an “equal weight” rating in a research report on Monday, December 15th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Waters in a research report on Wednesday, January 21st. Finally, William Blair initiated coverage on Waters in a research note on Monday, January 5th. They set an “outperform” rating on the stock. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, Waters has a consensus rating of “Moderate Buy” and a consensus price target of $398.61.

Institutional Investors Weigh In On Waters

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. MUFG Securities EMEA plc acquired a new position in shares of Waters in the 2nd quarter valued at about $61,000. State of Wyoming purchased a new position in Waters during the second quarter valued at approximately $75,000. Headlands Technologies LLC purchased a new position in Waters during the second quarter valued at approximately $135,000. EverSource Wealth Advisors LLC lifted its holdings in Waters by 82.9% in the second quarter. EverSource Wealth Advisors LLC now owns 386 shares of the medical instruments supplier’s stock valued at $135,000 after acquiring an additional 175 shares during the period. Finally, Sivia Capital Partners LLC purchased a new stake in Waters in the 2nd quarter worth approximately $232,000. 94.01% of the stock is owned by institutional investors and hedge funds.

About Waters

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.